Black Rose Industries Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/t1u7v0cvll1r7pkbrjva74bh.pdf

Key Takeaways


Q4 Performance: The Surge and Its Composition

Ambarish Daga: "In terms of the question on Q4, whether it was operational gain or just inventory gain, so I would say it is a mix of both... it is not just about inventory gain on a one-time basis, it is going to be sustainable as far as we can foresee."

Geopolitics: From Risk to Reliability


Manufacturing: Volume Growth and Strategic Reshaping


Project Pipeline: Piloting, Partnerships, and No Dates


Outlook: Subdued Near-Term, Pipeline-Led Recovery


Guidance & Commitments

CommitmentSpecificsTimeline
Top-line growthIncrease overall top line from previous year at current market prices, subject to market conditions and penetrationFY27
Capacity utilizationAchieve maximum possible utilization for manufactured productsFY27 and FY28
PAM solid commercializationAdvance from piloting to commercialization activitiesDuring the current year
Specialty amines decisionTake a decision on the Koei Chemicals joint projectDuring the current year
Merchant export recoveryStrong order pipeline to convert into healthy performanceQ1 FY27
New downstream acrylamide productsAdd to manufacturing offeringsFuture quarters (undated)
Ambarish Daga: "It is difficult to put down any number as an assumption because it will not hold much value. There are too many different factors that go into a number. So, I would rather you stay away from giving you any number."

Key Metrics

MetricQ4 FY26
Revenue growth38% YoY
EBITDA growth~90% YoY
EBITDA margin11%, up from 9.7% YoY
Earnings per shareImproved YoY
Dividend125% recommended for FY26
Manufacturing revenue share~35% of total revenue (FY26 full year), balance from distribution
Acrylamide liquid capacity32,000 MTPA, of which 20,000 MTPA for merchant sales
Acrylamide solid capacity3,600 MTPA
N-methylol acrylamide (NMA) capacity2,000 MTPA
Q4 EBITDA run-rate₹13 cr per quarter (per an analyst's math)
FY27 EBITDA target₹50 cr (per an analyst's math)